Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

OnQuality Pharma Raises $15 Million for Oncotherapy Side-Effect Drugs

publication date: Oct 30, 2019

QnQuality Pharmaceuticals of Shanghai-Seattle raised $15 million in a Series A funding led by Matrix Partners China and BioTrack Capital. QnQuality is developing first-in-class drugs to treat side-effects of oncotherapy, especially a hand-foot skin reaction in cancer patients treated with VEGF drugs. OQL011 has been approved to start Phase II trials in the US. Also participating in the funding were CASH Capital, backed by state-owned Chinese Academy of Sciences Holdings Company. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital